TW201605479A - 抗Muc１類美登素免疫綴合物抗體用於治療實體腫瘤之用途 - Google Patents

抗Muc１類美登素免疫綴合物抗體用於治療實體腫瘤之用途 Download PDF

Info

Publication number
TW201605479A
TW201605479A TW103126492A TW103126492A TW201605479A TW 201605479 A TW201605479 A TW 201605479A TW 103126492 A TW103126492 A TW 103126492A TW 103126492 A TW103126492 A TW 103126492A TW 201605479 A TW201605479 A TW 201605479A
Authority
TW
Taiwan
Prior art keywords
conjugate
antibody
group
seq
cell binding
Prior art date
Application number
TW103126492A
Other languages
English (en)
Chinese (zh)
Inventor
席爾菲 阿薩朵瑞恩
多明尼克 米格納德
Original Assignee
賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽諾菲公司 filed Critical 賽諾菲公司
Publication of TW201605479A publication Critical patent/TW201605479A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW103126492A 2013-08-02 2014-08-01 抗Muc１類美登素免疫綴合物抗體用於治療實體腫瘤之用途 TW201605479A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306119 2013-08-02

Publications (1)

Publication Number Publication Date
TW201605479A true TW201605479A (zh) 2016-02-16

Family

ID=49036539

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103126492A TW201605479A (zh) 2013-08-02 2014-08-01 抗Muc１類美登素免疫綴合物抗體用於治療實體腫瘤之用途

Country Status (12)

Country Link
US (1) US20160347856A1 (cg-RX-API-DMAC7.html)
EP (1) EP3027218A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016525560A (cg-RX-API-DMAC7.html)
KR (1) KR20160035600A (cg-RX-API-DMAC7.html)
CN (1) CN105592861A (cg-RX-API-DMAC7.html)
AU (1) AU2014298514A1 (cg-RX-API-DMAC7.html)
CA (1) CA2919932A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690321A1 (cg-RX-API-DMAC7.html)
IL (1) IL243843A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016001541A (cg-RX-API-DMAC7.html)
TW (1) TW201605479A (cg-RX-API-DMAC7.html)
WO (1) WO2015014879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109147874A (zh) * 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
GB201506388D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
CN105997942B (zh) * 2016-06-24 2019-01-29 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
CN112105384B (zh) * 2017-01-18 2024-08-23 苏州启航纳米药物有限公司 癌糖肽的单克隆和人源化抗体
EP3665161B1 (en) * 2017-08-09 2023-09-27 Helmholtz-Zentrum für Infektionsforschung GmbH New targeted cytotoxic ratjadone derivatives and conjugates thereof
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
BR112021008526A2 (pt) * 2018-11-02 2021-08-10 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752950B2 (en) * 1998-02-25 2002-10-03 Wakamoto Pharmaceutical Co., Ltd. Remedies for corneal epithelium disturbance
CN103554261B (zh) * 2003-07-21 2017-03-01 伊缪诺金公司 Ca6抗原特异性细胞毒性偶联物及其应用方法
MX2008002607A (es) * 2005-08-22 2008-03-19 Immunogen Inc Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo.
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
KR20120080611A (ko) * 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커

Also Published As

Publication number Publication date
IL243843A0 (en) 2016-04-21
EP3027218A1 (en) 2016-06-08
CA2919932A1 (en) 2015-02-05
WO2015014879A1 (en) 2015-02-05
AU2014298514A1 (en) 2016-03-10
JP2016525560A (ja) 2016-08-25
WO2015014879A9 (en) 2015-11-19
MX2016001541A (es) 2016-08-18
CN105592861A (zh) 2016-05-18
EA201690321A1 (ru) 2016-12-30
US20160347856A1 (en) 2016-12-01
KR20160035600A (ko) 2016-03-31

Similar Documents

Publication Publication Date Title
TW201605479A (zh) 抗Muc１類美登素免疫綴合物抗體用於治療實體腫瘤之用途
TWI873167B (zh) 以結合191p4d12蛋白質之抗體藥物結合物(adc)治療癌症
US20230087871A1 (en) Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
EP4426736A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
US20230181755A1 (en) Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
CN115427083A (zh) 含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
CN119604314A (zh) 抗gd2抗体、免疫偶联物及其治疗用途
US20230151088A1 (en) Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
CN120813387A (zh) 抗ceacam5免疫缀合物用于治疗表达ceacam5的神经内分泌癌症的用途
WO2017194568A1 (en) Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
RU2835019C1 (ru) Противоопухолевые комбинации, включающие конъюгаты на основе антитела к ceacam5, трифлуридин и типирацил
WO2024251733A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
CN118696060A (zh) 含有抗ceacam5抗体药物缀合物和抗vegfr-2抗体的抗肿瘤组合
CN120826244A (zh) 含有抗ceacam5抗体-药物缀合物、抗vegfr-2抗体和抗pd1/pd-l1抗体的抗肿瘤组合